Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

Company Overview

Amneal Pharmaceuticals, Inc. is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A. In 2018, the acquisition of Impax Laboratories expanded its specialty footprint and R&D capabilities, leading to the creation of Amneal Specialty. The company maintains research centers in New Jersey and India, where teams focus on formulation science, bioequivalence studies and advanced drug delivery technologies.

Amneal’s manufacturing network comprises facilities in the United States, Ireland and India, enabling the company to supply markets across North America, Europe and select emerging regions. Its vertically integrated model extends from active pharmaceutical ingredient (API) production to finished-dose manufacturing, supported by a global quality and regulatory framework. This structure allows Amneal to manage supply chain resilience and maintain cost efficiencies in a competitive generics landscape.

Leadership at Amneal is spearheaded by co-CEOs Chirag and Chintu Modgil, who bring experience in pharmaceutical operations and strategy. The executive team includes President Gregory Divis, overseeing commercial and pipeline functions, as well as a cohort of seasoned professionals in regulatory affairs, quality assurance and global manufacturing. Together, the leadership team aims to drive sustainable growth by expanding product offerings and enhancing patient access to affordable medicines.

Key Stats

• Today's Range: $10.19 to $10.30
• 50-Day Range: $7.83 to $10.55
• 52-Week Range: $6.68 to $10.68
• Volume: 99,078 shs
• Average Volume: 1.68 million shs
• Market Capitalization: $3.18 billion
• P/E Ratio: 1,023.52
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

Amneal Pharmaceuticals Stock Analysis - MarketRank™

Amneal Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 465th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Amneal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Amneal Pharmaceuticals has a consensus price target of $12.00, representing about 16.6% upside from its current price of $10.29.

Amount of Analyst Coverage

Amneal Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 13.21%

Earnings Growth

Earnings for Amneal Pharmaceuticals are expected to grow by 13.21% in the coming year, from $0.53 to $0.60 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amneal Pharmaceuticals is 1,030.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 233.14.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amneal Pharmaceuticals is 1,030.03, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 85.88.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.48% of the float of Amneal Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Amneal Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Amneal Pharmaceuticals has recently decreased by 1.17%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amneal Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Amneal Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.48% of the float of Amneal Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Amneal Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Amneal Pharmaceuticals has recently decreased by 1.17%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.37

News Sentiment

Amneal Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Amneal Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

Only 8 people have searched for AMRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added Amneal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Amneal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,700,624.00 in company stock.

Percentage Held by Insiders

26.56% of the stock of Amneal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 31.82% of the stock of Amneal Pharmaceuticals is held by institutions.

AMRX Stock Analysis - Frequently Asked Questions

How have AMRX shares performed this year?

Amneal Pharmaceuticals' stock was trading at $7.92 at the start of the year. Since then, AMRX stock has increased by 29.9% and is now trading at $10.29.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) issued its quarterly earnings results on Monday, July, 21st. The company reported $0.21 earnings per share for the quarter. The business earned $695.42 million during the quarter. Amneal Pharmaceuticals had a net margin of 0.12% and a negative trailing twelve-month return on equity of 189.49%.
Read the conference call transcript.

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' top institutional investors include Assenagon Asset Management S.A. (0.68%) and Voya Investment Management LLC (0.01%). Insiders that own company stock include Tushar Bhikhubhai Patel, Tpg Gp A, Llc, Gautam Patel, John Kiely, Andrew S Boyer, Nikita Shah and Jason B Daly.
View institutional ownership trends.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amneal Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), TotalEnergies (TTE), Voyager Therapeutics (VYGR), Broadcom (AVGO) and Waste Connections (WCN).

Company Calendar

• Last Earnings: 7/21/2025
• Today: 10/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AMRX
• Previous Symbol: NASDAQ:AMRX
• CIK: 1723128
• Web: amneal.com
• Phone: 908-947-3120
• Fax: 908-947-3146
• Employees: 8,100
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Amneal Pharmaceuticals: $12.00
• High Price Target: $14.00
• Low Price Target: $11.00
• Potential Upside/Downside: +16.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.01
• Trailing P/E Ratio: 1,033.53
• Forward P/E Ratio: 19.48
• P/E Growth: N/A
• Net Income: -$116.89 million
• Net Margins: 0.12%
• Pretax Margin: 3.13%
• Return on Equity: -189.49%
• Return on Assets: 6.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.43
• Quick Ratio: 0.88

Sales & Book Value

• Annual Sales: $2.85 billion
• Price / Sales: 1.14
• Cash Flow: $1.37 per share
• Price / Cash Flow: 7.55
• Book Value: ($0.35) per share
• Price / Book: -29.50

Miscellaneous

• Outstanding Shares: 314,079,000
• Free Float: 230,660,000
• Market Cap: $3.24 billion
• Optionable: Optionable
• Beta: 1.18